Last week, Rialto Markets Co-Founder and COO Joel Steinmetz was delighted to participate as a partner, speaker, and panellist at this year’s USA ’22 Emerging Medtech Summit event, taking place at Monarch Beach Resort, Dana Point, California.
The event provided highly innovative Medtech start-ups with the opportunity to present their medical devices such as robotics, artificial intelligence, mobile health, neurostimulation, neuromodulation, and nanotechnology to venture capital funds, private equity funds, SPACs, and strategic investors so both parties can deal-make and collaborate.
Joel Steinmetz took three key takeaways from this event:
- The benefits of Reg A+ for Medtech companies at LSI was quickly and well understood, with many stating, “Reg A+ is almost too good to be true”.
Joel Steinmetz commented: “You need to consider the totality of the cost, including hidden cost (as opposed to hidden fees). If you go through traditional capital raising avenues, you will give up multiples more in ownership stake than you will through Reg A. In essence, the cost paid for Reg A can be considered a small fee for retaining control of your company both regarding ownership stake and strategic vision and direction.” - Education for issuers on leveraging Reg A+ for a capital raise is key.
Joel Steinmetz went on to say: “The issuer’s desire to educate themselves and avail themselves of the Reg A path is strong, sincere, and timely if not somewhat urgent.” - Interest in Secondary Trading ATS’s (Alternative Trading System) was also high. Several issuers wanted to know if they could add their existing, seasoned shares on the ATS. The answer is yes (assuming they’re qualified).
Thank you to everyone who attended this year’s event to listen to and support Rialto Markets, we welcome anyone from the Medtech or Life Sciences space to reach out to us if they need any help or support.